Abstract:Abstract Conventional therapy in CLL is not curative, partly because minimal residual disease (MRD) is usually detectable after therapy. Recent therapeutic approaches achieve higher complete remission (CR) rates, and often aim for MRD eradication as this has repeatedly been shown to predict improved outcome. However, many different MRD techniques have been used to assess response, making it extremely difficult to interpret and compare different clinical trials. The aim of this international collaboration is to develop standardized flow cytometric and PCR approaches to MRD monitoring in CLL that are broadly applicable; to assess their relative sensitivity and specificity in a variety of laboratories; and to establish a standardized reporting convention to facilitate the interpretation of clinical trials. These techniques may be used as a benchmark for assessing response and comparing the efficacy of different therapeutic approaches. PCR approaches using consensus primers to the immunoglobulin heavy chain (IgH) gene are straightforward and frequently used, but have highly variable sensitivity between patients. In the proposed standardized method, the IgH gene is amplified using the BIOMED-2 primers (van Dongen et al, Leukemia 2003, 17:2257) and an allele-specific CDR3 primer is designed. CLL cells are identified by RQ-PCR using the allele-specific oligonucleotide (ASO) primer coupled with intronic JH primers and consensus reporter probes. The amount of PCR product is compared to a single copy housekeeping gene (albumin) to identify the number of CLL cells in the sample. This approach reproducibly quantitates as few as 1 CLL cell in 10,000 other leucocytes, and may provide qualitative information below this level. Multi-parameter flow cytometric analysis with combinations such as CD19/CD5/CD79b/CD20 is reported to have a sensitivity approaching that of ASO-PCR. However, such approaches are less effective in situations where normal B-cells lack CD20, e.g. in patients treated with combinations including rituximab and in normal bone marrow. To circumvent these problems, the group has tested 58 individual four-colour combinations of antibodies identified from protein expression profiling and previously published studies. CD79b/CD43/CD19/CD5, CD81/CD22/CD19/CD5, and CD20/CD38/CD19/CD5 provided the least inter-laboratory variation, independent of methodology. They show low contamination by non-CLL cells and were therefore selected as a core panel for MRD analysis. Dilutional studies indicate that a quantitative sensitivity equivalent for detection of 1 CLL cell in 10,000 leucocytes is achievable; the practical sensitivity is being tested in blinded dilutional analyses. The proposed flow cytometry approach is applicable to all sample types and all therapeutic regimes, and sufficiently rapid and sensitive to guide therapy to an MRD negative status in real time. The PCR approach is highly sensitive but more complex, and is most suited to retrospective response assessment of clinical trials. We have identified the appropriate standardized analytical methods for both techniques and are currently validating these findings. These approaches will allow direct comparison of efficacy between different clinical trials, allowing more rapid international progress towards identifying a curative approach.

Flow Cytometric MRD Detection in Selected Mature B-Cell Malignancies

The Evolving Landscape of Flowcytometric Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic Leukemia

Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemia

A 19‐color single‐tube full spectrum flow cytometry assay for the detection of measurable residual disease in acute myeloid leukemia

MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCR and ddPCR

Different Minimal Residual Disease Levels Between Childhood Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia Detected with Multi-Parameter Flow Cytometry.

Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia

International Standardized Approach to Molecular and Flow Cytometric Residual Disease Monitoring in CLL.

Multiparametric Flow Cytometry for MRD Monitoring in Hematologic Malignancies: Clinical Applications and New Challenges

[The Clinical Significance of Detecting Minimal Residual Disease in Acute Childhood B-cell Lymphoblastic Leukemia with Flow Cytometry].

Single-Tube 10-Fluorochrome Analysis for Efficient Flow Cytometric Evaluation of Minimal Residual Disease in Plasma Cell Myeloma

A High‐Sensitivity 10‐Color Flow Cytometric Minimal Residual Disease Assay in B‐Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2‐in‐106 and Is Superior to Standard Minimal Residual Disease Assay: A Study of 622 Patients

[Detection of Minimal Residual Disease in B Lineage Acute Lymphoblastic Leukemia by 4-Color Flow Cytometry].

Flow Cytometry Based Detection of MRD in Bone Marrow of Patients with Multiple Myeloma: A Comparison Between Fluorescent-Based Cytometry Versus Cytof

Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML)

Flow cytometric minimal residual disease measurement accounting for cytogenetics in children with non‐high‐risk acute lymphoblastic leukemia treated according to the ALL‐MB 2008 protocol

Minimal residual disease monitoring in acute myeloid leukemia: Focus on MFC‐MRD and treatment guidance for elderly patients

The kappa/lambda ratio of surface immunoglobulin light chain as a valuable parameter for MRD assessment in CLL with atypical immunophenotype

Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia

Methodological aspects of the detection of minimal residual disease in patients with acute leukemia

Old and New Concepts